海创药业(688302.SH)：上半年净亏损6185.32万元元

Core Viewpoint - Haichuang Pharmaceutical (688302.SH) reported a significant increase in revenue due to the approval and sales of its first Class 1 new drug, demonstrating the company's growth potential despite a net loss [1] Financial Performance - The company achieved operating revenue of 13.17 million yuan, representing a year-on-year growth of 0.84% [1] - The net profit attributable to shareholders was -61.85 million yuan, with a basic earnings per share of -0.62 yuan [1] Product Development - The revenue growth was primarily driven by the sales of the new drug, Deutetrabenazine soft capsules (Project No: HC-1119), which was approved for market on May 29, 2025, generating sales of 13.07 million yuan [1] - In the same period last year, the company had minimal revenue from material sales, indicating a significant shift in its revenue generation strategy [1]